https://www.selleckchem.com/pr....oducts/methyl-b-cycl
23). Changes in aBMD at the hip favored ZA at 4 months (mean difference 10.3-14.1%, p less then 0.01) and 12 months (mean difference 10.8-13.1%, p less then 0.02). At 4 months, changes in aBMD favored ZA at the distal femur (mean difference 6.0%, 95% CI 0.7-11.2, p less then 0.03) but not proximal tibia (mean difference 8.3%, 95% CI -6.9 to 23.6, p less then 0.23). Both groups declined in aBMD at 12 months, with no between group differences. CONCLUSION ZA administered ≤21 days of complete traumatic SCI maintains aB
Curtir
Comentario
Compartilhar
